- Home
- ATAI
as 04-22-2025 9:47am EST
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
| Founded: | 2018 | Country: | Germany |
| Employees: | N/A | City: | BERLIN |
| Market Cap: | 282.6M | IPO Year: | 2021 |
| Target Price: | $10.50 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.93 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.03 - $2.56 | Next Earning Date: | 05-14-2025 |
| Revenue: | $308,000 | Revenue Growth: | -1.91% |
| Revenue Growth (this year): | 65.58% | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of ATAI Life Sciences N.V. (ATAI)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Apeiron Investment Group Ltd. | ATAI | 10% Owner | Mar 24 '25 | Buy | $1.40 | 1,800,000 | $2,520,000.00 | 42,369,415 | |
| Johnson Anne Nagengast | ATAI | Chief Financial Officer | Mar 21 '25 | Sell | $1.35 | 33,545 | $45,285.75 | 140,045 | |
| Kirpekar Sahil | ATAI | Chief Business Officer | Mar 21 '25 | Sell | $1.35 | 48,563 | $65,560.05 | 115,636 | |
| Rao Srinivas | ATAI | See Remarks | Mar 21 '25 | Sell | $1.35 | 75,418 | $101,814.30 | 212,942 | |
| Short Glenn Frank | ATAI | Chief Scientific Officer | Mar 21 '25 | Sell | $1.35 | 13,161 | $17,767.35 | 42,333 | |
| Craig Kevin James | ATAI | Chief Medical Officer | Mar 21 '25 | Sell | $1.35 | 11,563 | $15,610.05 | 8,437 | |
| Apeiron Investment Group Ltd. | ATAI | 10% Owner | Feb 14 '25 | Buy | $2.10 | 10,835,718 | $22,755,007.80 | 42,369,415 |
Latest ATAI Life Sciences N.V. News
ATAI Breaking Stock News: Dive into ATAI Ticker-Specific Updates for Smart Investing
TipRanks
11 days ago
Psychedelic: Clearmind initiates U.S. clinical site for CMND-100 trial
TipRanks
a month ago
Psychedelic: Exclusive talk with biotech company Clearmind Medicine
TipRanks
a month ago
Psychedelic: atai Life Sciences, NRx report quarterly results
Simply Wall St.
a month ago
Atai Life Sciences Full Year 2024 Earnings: Misses Expectations
GlobeNewswire
a month ago
atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
TipRanks
a month ago
Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial
GlobeNewswire
a month ago
atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression
GlobeNewswire
2 months ago
atai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression
Compare ATAI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ATAI ATAI Life Sciences N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.